Revance Therapeutics RVNC 深 滬
已收盤 02-06 16:00:00 美东时间
3.65
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 3.65
- 總市值 3.80亿
- 52周最高 7.56
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.30
- 委 比 0.00%
- 總股本 1.04亿
- 歷史最高 42.41
- 量 比 0
- 振 幅 0.00%
- 歷史最低 2.30
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多RVNC Lawsuit Alert! Class Action Against Revance Therapeutics, Inc.
Aclass actionlawsuit was filed against Revance Therapeutics, Inc. (...
2025-02-21 19:59
Teoxane withdraws takeover offer for Revance Therapeutics
Teoxane withdrew its $3.60 a share offer for Revance Therapeutics after Crown Labs raised its offer to $3.65. Revance ticked lower by 0.3% in premarket trading. Teoxane said that committed financing i...
2025-01-30 22:16
BRIEF-Crown Laboratories And Revance Amend A&R Merger Agreement
Jan 21 (Reuters) - Revance Therapeutics Inc RVNC.O: CROWN LABORATORIES AND REVANCE AMEND THE A&R MERGER AGREEMENT TO INCREASE OFFER PRICE TO $3.65 PER SHARE AND EXTEND EXISTING TENDER OFFER INCREASED ...
2025-01-21 21:43
BUZZ-U.S. STOCKS ON THE MOVE-Henry Schein, natgas firms, Citigroup
Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes rose on...
2025-01-07 00:05
BUZZ-Revance Therapeutics gains after Teoxane's buyout proposal
** Shares of anti-wrinkle injection maker Revance Therapeutics RVNC.O gain 15.7% to $3.57 ** Privately held Swiss medical aesthetics company Teoxane proposed to acquire RVNC for $3.60 per share in cas...
2025-01-06 22:58
Revance Therapeutics jumps after Teoxane offers $3.60 a share
Revance Therapeutics (NASDAQ:RVNC) soared 16% after Teoxane offered to purchase the company for $3.60 a share in cash, above Crown Therapeutics $3.10 a share deal. Teoxane, which beneficially owns 6....
2025-01-06 22:50
美股大行评级 | 潜在涨幅265%！Humacyte获机构上调目标价至17美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1078254829883351040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Benchmark：维持Humacyte(HUMA)"买入"评级，目标价从15美元升至17美元</p> <p>• Evercore ISI集团：维持BridgeBio Pharma(BBIO)"跑赢大市"评级，目标价从45
2024-12-24 09:30
Key deals for the week: Patterson, Hershey & Mondelez, AIG & Nippon and more
A quick look at a list of key deals reported this week across sectors: Major healthcare deals include, Patterson Companies (PDCO) that jumped 34% on Wednesday, after it said it will be acquired by Pat...
2024-12-14 21:25
Mizuho Maintains Neutral on Revance Therapeutics, Lowers Price Target to $3.1
Mizuho analyst Vamil Divan maintains Revance Therapeutics (NASDAQ:RVNC) with a Neutral and lowers the price target from $6.66 to $3.1.
2024-12-10 21:09
Revance Therapeutics plunges after Crown Labs cuts takeover price in half
Revance Therapeutics (RVNC) sunk 20% in premarket trading after it agreed to a revised deal with Crown Laboratories, with the takeover price cut by more than half. Revance (NASDAQ:RVNC) will now rece...
2024-12-09 21:55
